辰欣药业
(603367)
| 流通市值：61.17亿 | | | 总市值：61.17亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 920,204,017.65 | 3,981,572,232.95 | 3,002,250,189.03 | 2,070,524,393.73 |
| 营业收入 | 920,204,017.65 | 3,981,572,232.95 | 3,002,250,189.03 | 2,070,524,393.73 |
| 二、营业总成本 | 741,656,866.42 | 3,483,462,580.81 | 2,615,901,369.99 | 1,800,515,626.8 |
| 营业成本 | 370,718,292.66 | 1,729,094,050.53 | 1,285,236,267.21 | 874,863,330.11 |
| 税金及附加 | 11,884,592.12 | 48,830,120.32 | 36,479,943.59 | 25,392,380.03 |
| 销售费用 | 227,815,118.85 | 1,093,997,243.75 | 820,785,390.01 | 599,247,430.73 |
| 管理费用 | 63,297,807.13 | 301,383,573.72 | 224,841,086.04 | 139,107,635.89 |
| 研发费用 | 73,643,696.38 | 342,641,077.12 | 272,306,294.13 | 179,089,288.76 |
| 财务费用 | -5,702,640.72 | -32,483,484.63 | -23,747,610.99 | -17,184,438.72 |
| 其中:利息费用 | 232,645.31 | 6,946,102.2 | 5,684,632.21 | 2,688,527.69 |
| 其中:利息收入 | 6,458,310.27 | 39,569,027.81 | 28,654,750.81 | 20,045,163.88 |
| 加:公允价值变动收益 | 5,340,389.94 | 10,528,296.23 | 24,844,374.41 | 8,425,105.66 |
| 加:投资收益 | 27,630,033.95 | 62,304,296.38 | 23,637,115.57 | 18,311,692.4 |
| 资产处置收益 | 434,730.77 | -139,530.24 | 13,294.63 | 26,289.19 |
| 资产减值损失(新) | -42,046,125.66 | -56,025,858.73 | -39,585,051.66 | -37,777,561.67 |
| 信用减值损失(新) | -13,397,494.28 | 4,163,418.64 | -5,285,220.61 | -8,393,886.31 |
| 其他收益 | 3,850,265.59 | 53,107,499.08 | 45,839,852.59 | 39,519,346.39 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 160,358,951.54 | 572,047,773.5 | 435,813,183.97 | 290,119,752.59 |
| 加:营业外收入 | 471,481.27 | 4,897,731.64 | 3,928,523.8 | 2,679,698.69 |
| 减:营业外支出 | 808,855.25 | 1,172,145.71 | 799,249.41 | 736,054.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 160,021,577.56 | 575,773,359.43 | 438,942,458.36 | 292,063,396.45 |
| 减:所得税费用 | 15,409,975.26 | 60,832,924.8 | 35,590,147.65 | 18,346,934.41 |
| 六、净利润 | 144,611,602.3 | 514,940,434.63 | 403,352,310.71 | 273,716,462.04 |
| 持续经营净利润 | 144,611,602.3 | 514,940,434.63 | 403,352,310.71 | 273,716,462.04 |
| 归属于母公司股东的净利润 | 143,544,555.3 | 508,906,193.71 | 398,119,097.94 | 270,316,954.65 |
| 少数股东损益 | 1,067,047 | 6,034,240.92 | 5,233,212.77 | 3,399,507.39 |
| (一)基本每股收益 | 0.32 | 1.12 | 0.88 | 0.6 |
| (二)稀释每股收益 | 0.32 | 1.12 | 0.88 | 0.6 |
| 八、其他综合收益 | 455,209.39 | -21,088.5 | -656,483.48 | 451,365.02 |
| 归属于母公司股东的其他综合收益 | 455,209.39 | -21,088.5 | -656,483.48 | 451,365.02 |
| 九、综合收益总额 | 145,066,811.69 | 514,919,346.13 | 402,695,827.23 | 274,167,827.06 |
| 归属于母公司股东的综合收益总额 | 143,999,764.69 | 508,885,105.21 | 397,462,614.46 | 270,768,319.67 |
| 归属于少数股东的综合收益总额 | 1,067,047 | 6,034,240.92 | 5,233,212.77 | 3,399,507.39 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |